Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02773732 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)
A Phase 1 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02773732 is a Phase 1 study that was terminated before completion, run by University of Florida. The registered enrollment target is 11 participants.
The verdict
NCT02773732, a Phase 1 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of the first part of this study is to establish the maximum tolerated dose (MTD) of oral ciprofloxacin when given in combination with a fixed dose of oral etoposide in patients with resistant acute myeloid leukemia (AML). The purpose of the second part of this study is to determine if the established dose of oral ciprofloxacin in combination with oral etoposide is effective in the treatment of patients with resistant AML.
Interventions
- DRUG Etoposide
- DRUG Ciprofloxacin 500 mg
- DRUG Ciprofloxacin 750 MG
- DRUG Ciprofloxacin 1000 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-12-16 |
| Est. Completion | 2021-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02773732
The ClinicalTrials.gov registry entry for NCT02773732 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Etoposide is the first listed.
NCT02773732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02773732 about?
NCT02773732 is a clinical study titled "Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)". The purpose of the first part of this study is to establish the maximum tolerated dose (MTD) of oral ciprofloxacin when given in combination with a fixed dose of oral etoposide in patients with resistant acute myeloid leukemia (AML). The purpose of the second part of this study is to determine if th...
What is the current status of trial NCT02773732?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2016-12-16. Estimated completion is 2021-11-15.
What interventions are being tested in trial NCT02773732?
The interventions under investigation include: Etoposide (DRUG), Ciprofloxacin 500 mg (DRUG), Ciprofloxacin 750 MG (DRUG), Ciprofloxacin 1000 MG (DRUG).
Who is sponsoring clinical trial NCT02773732?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.